PharmaTutor (January- 2014)
ISSN: 2347 - 7881
Received On: 28/12/2013; Accepted On: 04/01/2014; Published On: 15/01/2014
About Authors: Keyur S. Patel*, Mital Mehta
Department of Pharmacology,
Anand Pharmacy College, Anand,
ABSTRACT: Drug-induced liver injury (DILI) has become a leading cause of severe liver disease and withdrawal of an approved drug from the market. DILI accounts for acute liver failure, liver transplantation or death in the United States today. A recent retrospective study indicates that the risk of DILI is enhanced when the administered daily dosage is higher than 50 mg or when the drug undergoes significant liver metabolism. Hence airs a major clinical and regulatory challenge.
This review sum up direct mitochondrial impairment and Specific drug induced mitochondrial dysfunction, current mechanistic concepts of DILI in a 2-step model that limits its principle mechanisms to this main ways of initial injury. Umpteen Studies that evaluate the risk of hepatotoxicity from Statins in Hyperlipidemic Patients. In this article, It will review the pathogenesis of drug induced mitochondrial liver toxicity and deleterious consequences of Atorvastatin.
How to cite this article: KS Patel, M Mehta, Drug Induced Mitochondrial Toxicity: Mechanistic Diversity and Deleterious Consequences for the liver, PharmaTutor, 2014, 2(1), 33-39